Transanal Radiofrequency Treatment of Fecal Incontinence

Policy # 00571
Original Effective Date: 01/17/2018
Current Effective Date: 01/17/2018

Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc. (collectively referred to as the “Company”), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

Services Are Considered Investigational
Coverage is not available for investigational medical treatments or procedures, drugs, devices or biological products.

Based on review of available data, the Company considers transanal radiofrequency (RF) therapy as a treatment of fecal incontinence to be investigational.*

Policy Guidelines
The Secca procedure may be performed on an outpatient basis using conscious sedation and a local anesthetic.

Background/Overview
Fecal Incontinence
Fecal incontinence is the involuntary leakage of stool from the rectum and anal canal. Fecal continence depends on a complex interplay of anal sphincter function, pelvic floor function, stool transit time, rectal capacity, and sensation. Etiologies vary and include injury from vaginal delivery, anal surgery, neurologic disease, and the normal aging process. Estimated prevalence is 8% of the adult population.

Treatment
Medical management includes dietary measures, such as the addition of bulk-producing agents to the diet and elimination of foods associated with diarrhea; antidiarrheal drugs for mild incontinence; bowel management programs, commonly used in patients with spinal cord injuries; and biofeedback. Surgical approaches primarily include sphincteroplasty, although more novel approaches, such as sacral neuromodulation or creation of an artificial anal sphincter, may be attempted in patients whose only other treatment option is the creation of a stoma. RF energy also has been investigated as a minimally invasive treatment of fecal incontinence, a procedure referred to as the Secca™ procedure. In this outpatient procedure using conscious sedation, RF energy is delivered to the sphincteric complex of the anal canal to create discrete thermal lesions. Over several months, these lesions heal and the tissue contracts, changing the tone of the tissue and potentially improving continence.

RF energy is a surgical tool that has been used for tissue ablation and more recently for tissue remodeling. For example, RF energy has been investigated as a treatment for gastroesophageal reflux disease (i.e., the Stretta procedure), in which RF lesions are designed to alter the biomechanics of the lower esophageal sphincter; in orthopedic procedures to remodel the joint capsule; or in an intradiscal electrothermal annuloplasty procedure, in which the treatment is intended in part to modify and strengthen the disc annulus. In all of these procedures, nonablative levels of RF thermal energy are used to alter collagen fibrils, which results in a healing response characterized by fibrosis. Recently, RF energy has been explored as a minimally invasive treatment option for fecal incontinence.

©2018 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
FECAL INCONTINENCE

No trials comparing transanal RF treatment of fecal incontinence with available alternative treatments have been identified. The literature search to date has identified 8 nonrandomized studies on this procedure.

Systematic Reviews
In 2016, an Agency for Healthcare Research and Quality Comparative Effectiveness Review assessed surgical treatments for fecal incontinence, including transanal RF treatment. Reviewers identified only case series, which they addressed only under a key question related to adverse effects, not a key question related to comparative effectiveness. Reviewers concluded that the evidence for transanal RF treatment was insufficient to support its use for fecal incontinence.

Noncomparative Studies
Abbas et al (2012) retrospectively reviewed 27 patients who underwent the Secca procedure during a 6-year period (2004-2010) at a single medical center. Thirty-one procedures were performed for moderate-to-severe fecal incontinence. Most patients were women (mean age, 64 years), and the most common cause of incontinence was obstetrical injury. The median length of symptoms was 3 years. Biofeedback had failed in more than half of patients, and more than 20% of patients had previous surgical intervention to treat incontinence. No major complications occurred after the Secca procedure, and minor complications were observed in 5 (19%) patients (anal bleeding in four, swelling of the vulva in one). A treatment response was noted in 21 (78%); mean Cleveland Clinic Florida Fecal Incontinence (CCF-FI) score was 16 at baseline and 10.9 3 months postoperatively. Previous studies have suggested that a CCF-FI score greater than 9
indicates a significant impairment of quality of life. However, in the Abbas study, only 6 (22%) patients had a sustained long-term response without any additional intervention, and 14 (52%) patients underwent or were awaiting additional intervention for persistent or recurrent incontinence over a mean follow-up period of 40 months.

In 2003, Efron et al published an open-label, single-arm, nonrandomized study of 50 patients who underwent the Secca procedure and was followed for 6 months. Patients served as their own controls. The study assessed change in fecal incontinence symptom scores and quality of life between baseline and follow-up. Fecal incontinence was assessed with CCF-FI score, and quality of life was assessed with the Fecal Incontinence Quality of Life (FIQL) score. Both the CCF-FI and FIQL scores improved in a steady, gradual manner over a 6-month period, from 14.6 to 11.1 for the CCF-FI and from 2.5 to 3.1 for the FIQL. Of 44 patients who had an initial baseline CCF-FI score greater than 9, a total of 15 (34%) achieved CCF-FI score less than 10 at 6 months. Improvement also was assessed using the Medical Outcomes Study 36-Item Short-Form Health Survey, focusing on mental and social parameters. Mean social function subscore improved from 64.3 to 34.4, and mental health subscore improved from 65.8 to 73.8. Fourteen-day diary data demonstrated significant improvement in all 9 parameters (e.g., days with any fecal incontinence dropped from 10 in a 14-day period to 7). In contrast, there were no differences in objective measures of anal sphincter function (i.e., there were no differences in manometry measures, rectal sensation volumes, pudendal nerve motor latency, or internal or external sphincter defects), as noted on endoanal ultrasound. Authors noted that determining the mechanism of action for the procedure was not a study objective. Three significant procedure-related complications occurred during the trial. Two patients developed anal ulceration, and one developed bleeding from a hemorrhoidal vein. Twenty-six minor adverse events occurred, including minor bleeding in 5 patients, transient worsening of incontinence in 4 patients, and anal pain in 5 patients.

Felt-Bersma et al (2007) published results of an uncontrolled study on the Secca procedure in 11 women with fecal incontinence who underwent baseline and posttreatment testing. Six (55%) patients reported improvement; Vaizey Incontinence Questionnaire scores improved 13%, but no changes were observed in anal manometry, rectal compliance measurement, or 3-dimensional anal ultrasound. Postoperative pain was reported to be slight in 8 (73%) patients, moderate in 2, and severe in 1. Investigators suggested that this procedure merited further testing. Lam et al (2014) reported 3-year outcomes of this cohort plus 20 other patients who underwent the Secca procedure for fecal incontinence. Of the total cohort of 31 patients, 5 (16%) maintained a clinically significant response (defined as ≥50% reduction in Vaizey Incontinence Questionnaire score) for 6 months, 3 (10%) maintained response for 1 year, and 2 (6%) maintained response for 3 years. Improvements from baseline in anal manometry (increased anorectal pressures or enhanced rectal compliance) were not observed.

Ruiz et al (2010) reported on 1-year quality of life and continence outcomes for a series of 24 patients treated with RF energy for fecal incontinence between 2003 and 2004. Twelve-month results were available for 16 (67%) patients. Mean CCF-FI score improved from 15.6 at baseline to 12.9 at 12 months (p=0.035). Mean FIQL score improved in all subsets except for the depression subscore. Authors’ conclusions on the actual clinical significance of this improvement were uncertain.
Three additional very small case series (n=15, 19, 8) were performed outside the United States. In two of them, no clear benefit was noted for the procedure.

**Section Summary: Noncomparative Studies**

A small body of observational studies or noncomparative, single-arm trials have reported on changes in incontinence symptoms after the Secca procedures. Given the small number of studies conducted and the limitations of those trials (i.e., small number of patients, lack of control arm and randomization, inconsistencies with inclusion and exclusion criteria, short-term follow-up), the efficacy of RF therapy for fecal incontinence is not supported in the literature.

**SUMMARY OF EVIDENCE**

For individuals who have fecal incontinence who receive transanal RF treatment, the evidence includes 8 nonrandomized studies. Relevant outcomes are symptoms, change in disease status, quality of life, and treatment-related morbidity. Studies include a small number of patients, and estimates of treatment differences are very imprecise. Study follow-up periods vary and need to be considerably longer and involve larger numbers of patients to evaluate long-term outcomes properly. Three-year follow-up of a small cohort showed decrement in response over time. Multicenter randomized controlled trials with sufficient power are required to evaluate the continuing use of this procedure as an alternative to other surgical interventions, physical therapies, or as an adjunctive treatment option for fecal incontinence. The evidence is insufficient to determine the effects of the technology on health outcomes.

**References**


©2018 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Transanal Radiofrequency Treatment of Fecal Incontinence

Policy # 00571
Original Effective Date: 01/17/2018
Current Effective Date: 01/17/2018


Policy History
Original Effective Date: 01/17/2018
Current Effective Date: 01/17/2018
01/04/2018 Medical Policy Committee review
01/17/2018 Medical Policy Implementation Committee approval. New policy.
Next Scheduled Review Date: 01/2019

Coding
The five character codes included in the Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines are obtained from Current Procedural Terminology (CPT®), copyright 2017 by the American Medical Association (AMA). CPT is developed by the AMA as a listing of descriptive terms and five character identifying codes and modifiers for reporting medical services and procedures performed by physician.

The responsibility for the content of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines is with Blue Cross and Blue Shield of Louisiana and no endorsement by the AMA is intended or should be implied. The AMA disclaims responsibility for any consequences or liability attributable or related to any use, nonuse or interpretation of information contained in Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. Any use of CPT outside of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines should refer to the most current Current Procedural Terminology which contains the complete and most current listing of CPT codes and descriptive terms. Applicable FARS/DFARS apply.

CPT is a registered trademark of the American Medical Association.

Codes used to identify services associated with this policy may include (but may not be limited to) the following:

<table>
<thead>
<tr>
<th>Code Type</th>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPT</td>
<td>46999</td>
</tr>
<tr>
<td>HCPCS</td>
<td>No codes</td>
</tr>
<tr>
<td>ICD-10 Diagnosis</td>
<td>All related diagnoses</td>
</tr>
</tbody>
</table>

*Investigational – A medical treatment, procedure, drug, device, or biological product is Investigational if the effectiveness has not been clearly tested and it has not been incorporated into standard medical practice. Any determination we make that a medical treatment, procedure, drug, device, or biological product is Investigational will be based on a consideration of the following:

©2018 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Transanal Radiofrequency Treatment of Fecal Incontinence

Policy # 00571
Original Effective Date: 01/17/2018
Current Effective Date: 01/17/2018

A. Whether the medical treatment, procedure, drug, device, or biological product can be lawfully marketed without approval of the U.S. Food and Drug Administration (FDA) and whether such approval has been granted at the time the medical treatment, procedure, drug, device, or biological product is sought to be furnished; or

B. Whether the medical treatment, procedure, drug, device, or biological product requires further studies or clinical trials to determine its maximum tolerated dose, toxicity, safety, effectiveness, or effectiveness as compared with the standard means of treatment or diagnosis, must improve health outcomes, according to the consensus of opinion among experts as shown by reliable evidence, including:

1. Consultation with the Blue Cross and Blue Shield Association technology assessment program (TEC) or other nonaffiliated technology evaluation center(s);
2. Credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community; or
3. Reference to federal regulations.

‡ Indicated trademarks are the registered trademarks of their respective owners.

NOTICE: Medical Policies are scientific based opinions, provided solely for coverage and informational purposes. Medical Policies should not be construed to suggest that the Company recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service, or any particular course of treatment, procedure, or service.